APA (7th ed.) Citation

Autio, K. A., Boni, V., Humphrey, R. W., & Naing, A. (2020). Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clinical cancer research, 26(5), 984. https://doi.org/10.1158/1078-0432.CCR-19-1457

Chicago Style (17th ed.) Citation

Autio, Karen A., Valentina Boni, Rachel W. Humphrey, and Aung Naing. "Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology." Clinical Cancer Research 26, no. 5 (2020): 984. https://doi.org/10.1158/1078-0432.CCR-19-1457.

MLA (9th ed.) Citation

Autio, Karen A., et al. "Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology." Clinical Cancer Research, vol. 26, no. 5, 2020, p. 984, https://doi.org/10.1158/1078-0432.CCR-19-1457.